Regeneron Pharmaceuticals Inc (REGN) Now Covered by CIBC

Equities researchers at CIBC began coverage on shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in a report issued on Friday. The brokerage set a “market perform” rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the company. Evercore ISI set a $421.00 price target on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, January 8th. Leerink Swann set a $448.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, February 11th. Chardan Capital raised Regeneron Pharmaceuticals from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $300.00 to $350.00 in a report on Monday, December 12th. Vetr cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $401.26 price target on the stock. in a report on Monday, December 12th. Finally, BTIG Research reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, November 17th. Fourteen analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $434.97.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 382.02 on Friday. The company has a market capitalization of $40.29 billion, a PE ratio of 49.62 and a beta of 1.44. The firm’s 50-day moving average is $371.86 and its 200-day moving average is $379.60. Regeneron Pharmaceuticals has a 12 month low of $325.35 and a 12 month high of $452.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, February 9th. The biopharmaceutical company reported $3.04 EPS for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.01. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The company had revenue of $1.23 billion for the quarter, compared to analysts’ expectations of $1.30 billion. During the same period in the previous year, the firm earned $2.83 EPS. The firm’s revenue was up 11.7% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals will post $12.95 EPS for the current fiscal year.

Your IP Address:

In other news, major shareholder Sanofi acquired 87,298 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 11th. The shares were acquired at an average price of $369.71 per share, with a total value of $32,274,943.58. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 10.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. IFP Advisors Inc increased its position in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 80 shares in the last quarter. WFG Advisors LP increased its position in Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 7,415 shares in the last quarter. Alpha Windward LLC increased its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 34 shares in the last quarter. Live Your Vision LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at $157,000. Finally, Blenheim Capital Management BV bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $160,000. 68.83% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

5 Day Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Barclays Comes Up Short, Shares Fall
Barclays Comes Up Short, Shares Fall
Revenue at Twitter Beats the Street, Monthly Users Increase
Revenue at Twitter Beats the Street, Monthly Users Increase
McDonald’s Ordering Via Mobile Could Give Handsome Return
McDonald’s Ordering Via Mobile Could Give Handsome Return
Mattel CEO Promises Growth Following Sales Slump
Mattel CEO Promises Growth Following Sales Slump
Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor


© 2006-2017 Ticker Report. Google+.